TL;DR: A 2026 preprint in medRxiv found that brain-derived p-tau217%, a blood marker designed to isolate central nervous system tau, classified Alzheimer disease pathology better than standard plasma p-tau217 in several Alzheimer cohorts. Key Findings CNS-selective ratio: The proposed marker, brain-derived p-tau217%, estimates the share of circulating tau that is both brain-derived and phosphorylated at …
TL;DR: A 2026 review in Drug Design, Development and Therapy argued that glucagon-like peptide-1 (GLP-1) receptor agonists, drugs that mimic a metabolic hormone involved in glucose control, have credible brain-protection mechanisms, but clinical evidence for neurological disorders remains mixed. Key Findings 15-page review: Li et al. summarized GLP-1 receptor agonist mechanisms and evidence across neurodegenerative, …
TL;DR: A 2025 study in Neurology used a Kaiser Permanente target-trial emulation and found that starting a statin was not linked to higher or lower Alzheimer disease or related dementia incidence after the first year. The first-year diagnosis increase likely reflected more medical contact after a new prescription. Key Findings No difference after year one: …
TL;DR: A 2026 preprint in medRxiv reported that a urine beta-amyloid protein test kit separated mild cognitive impairment or Alzheimer’s disease from healthy controls in a multicenter Chinese sample, while a 51,187-person community screen showed age-related positive rates. Key Findings 898-person validation sample: The multicenter case-control arm included 266 healthy controls, 167 people with mild …
TL;DR: A 2026 computational study in PLOS One used GEO Alzheimer’s datasets, 130 machine-learning models, and molecular simulations to identify eight candidate genes that may sit in a trichostatin A-related Alzheimer’s disease network. Key Findings 949 predicted TSA targets: The analysis started with predicted human protein targets for trichostatin A, a histone deacetylase inhibitor. Five …
TL;DR: A 2026 preprint on medRxiv found that older adults with mild-cognitive-impairment-level scores showed different resting facial action patterns than healthy controls, especially upper lip raiser, lip tightener, and lip suck measures. Key Findings MCI-level comparison: The study included 45 older adults and compared 31 participants in the MCI-level group with 14 healthy controls. MoCA-defined …
TL;DR: A 2025 mouse study in eNeuro reported that inhaled cannabidiol reduced IDO and cGAS pathway activity and lowered pro-inflammatory cytokines in male 5XFAD Alzheimer’s model mice. Key Findings 5XFAD model: The study used male 5XFAD transgenic mice, a common amyloid-heavy Alzheimer’s disease model. Inhaled CBD: Cannabidiol was administered by inhalation rather than by oral …
TL;DR: A 2026 preprint in medRxiv used amyloid positron-emission tomography, tau molecular imaging, and structural MRI to build individualized Alzheimer’s disease biomarker axes from ADNI and validate them in OASIS. Key Findings 12,430 ADNI images: The pipeline harmonized longitudinal amyloid-beta and tau positron-emission tomography images plus T1 MRI gray matter images from ADNI. 4,958 OASIS …
TL;DR: A 2026 study in Acta Neuropathologica Communications used Boolean-network AI analysis of Alzheimer’s RNA-seq data to identify a 40-gene disease signature and validate CgA-KO/PS19 mice as a model of asymptomatic Alzheimer’s-like resilience. Key Findings 289-person training set: Boolean Network Explorer was trained on cortical RNA-seq data from 70 cognitively normal controls and 219 Alzheimer’s …
TL;DR: A 2026 Molecular Psychiatry study tested Regional Vulnerability Index for Alzheimer’s disease (RVI-AD), a structural-MRI score of how closely a person’s brain pattern resembles amyloid-positive Alzheimer’s disease, and found that higher RVI-AD predicted conversion from mild cognitive impairment to dementia most strongly in the first 3 years. Key Findings 571-person reference map: Researchers built …
